Hopstem secures its first Series C financing to advance hNPC01 for neurological conditions. New investors include Tasly Capital, Haibang Investment, and Guangzhou Health Industry Investment.
Round Type
Series C
HoustonBiotechnologyHealth CareTherapeuticsInvestors
Description
Hopstem Biotechnology Inc. announced the first closing of its Series C financing aimed at accelerating clinical development for hNPC01. The financing includes participation from new and existing investors. Hopstem plans to use the funds to accelerate clinical programs for its therapy
Quick answer
Hopstem Biotechnology raised an undisclosed amount in a Series C round, dated August 10, 2026. Investors: Longmen Capital, Guangzhou Health Industry Investment, Haibang Investment and Tasly Capital. Hopstem Biotechnology is based in Houston, Texas, United States.
- How much did Hopstem Biotechnology raise?
- Hopstem Biotechnology raised an undisclosed amount in a Series C round on August 10, 2026.
- Who invested in Hopstem Biotechnology?
- Longmen Capital, Guangzhou Health Industry Investment, Haibang Investment and Tasly Capital are named as investors in this round.
- What does Hopstem Biotechnology do?
- Hopstem Biotechnology Inc. is a Houston-based biotechnology company focused on developing induced pluripotent stem cell-derived neural cell therapies.
- Where is Hopstem Biotechnology based and how big is it?
- Hopstem Biotechnology is based in Houston, Texas, United States.
- Who are the decision-makers at Hopstem Biotechnology?
- Fundz holds 2 contacts at Hopstem Biotechnology, including the CEO. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biotechnology around the same time
Companies in the same sectors as Hopstem Biotechnology that raised within 45 days of this round, from Fundz verified event records.
- Rejuvenation Technologies raised an undisclosed amount on September 24, 2026.
- Kasvu Therapeutics raised $34M (Series A) on September 24, 2026.
- ViferaXS raised $14M (Series A) on September 23, 2026.
- Kinoxis Therapeutics raised $5M (Seed) on September 23, 2026.
- Aqua Medical raised an undisclosed amount (Series B) on September 23, 2026.
- Anacalypsis Therapeutics raised an undisclosed amount (Pre-Seed) on September 21, 2026.
Who to call at Hopstem Biotechnology, and when
A new round usually means Hopstem Biotechnology is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Hopstem Biotechnology raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Hopstem Biotechnology, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Hopstem Biotechnology. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Hopstem Biotechnology raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Hopstem Biotechnology raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.